Prednisone placebo

DRUG6 trials

Conditions

Alcohol-associated HepatitisChronic Obstructive Pulmonary DiseaseGiant Cell ArteritisProstate NeoplasmsRheumatoid Arthritis• ACTH-Dependent Cushing’s Syndrome. • Pituitary-dependent Cushing´s syndrome.

Phase 2

A Study Of PF-04171327 In The Treatment Of The Signs And Symptoms Of Rheumatoid Arthritis

CompletedNCT00938587

PfizerRheumatoid Arthritis

Start: 2009-10-07End: 2010-07-29Updated: 2023-11-22

Safety & Efficacy of BCT197A2201 in COPD Patients Presenting With an Exacerbation

CompletedNCT01332097

Mereo BioPharmaChronic Obstructive Pulmonary Disease

Start: 2011-03-31End: 2013-05-31Updated: 2023-03-21

Integrated Therapies for Alcohol Use in Alcohol-associated Liver Disease (ITAALD) Trial

RecruitingNCT07060638

Samer GawriehAlcohol-associated Hepatitis

Start: 2026-01-27End: 2029-12-01Target: 216Updated: 2026-07-15

A Multicenter, Phase 2/3, Dose Range Finding Study to Evaluate the Efficacy and Safety of Atumelnant in Adults with ACTH-Dependent Cushing’s Syndrome (ADCS) Including an Open-Label Extension for Long-Term Assessment. (EQUILIBRIUM-ADCS)

Not yet recruitingCTIS2025-522648-42-01

Crinetics Pharmaceuticals Inc.• ACTH-Dependent Cushing’s Syndrome. • Pituitary-dependent Cushing´s syndrome.

Target: 25Updated: 2026-09-29

Phase 3

A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)

CompletedNCT01715285

Janssen Research & Development, LLCProstate Neoplasms

Start: 2013-02-12End: 2022-02-13Updated: 2025-02-04

An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA)

CompletedNCT01791153

Hoffmann-La RocheGiant Cell Arteritis

Start: 2013-07-22End: 2018-06-04Updated: 2020-02-06

British Journal of Urology2026-10-05

Impact of BRCA alterations on androgen receptor pathway inhibition treatment outcome in advanced prostate cancer.

Journal of Clinical Oncology2025-05-28

Clinical Outcomes of First Subsequent Therapies After Abiraterone Acetate Plus Prednisone for High-Risk Metastatic Castration-Sensitive Prostate Cancer in the LATITUDE Study.

2022-11-282 citations

Intravenous tocilizumab for the treatment of giant cell arteritis: a phase Ib dose-ranging pharmacokinetic bridging study.

2022-06-047 citations

PSA-progression only in high-risk, metastatatic hormone-sensitive prostate cancer patients treated with abiraterone in the LATITUDE trial.

Journal of Clinical Oncology2022-02-16

Estimation of Overall Survival with Subsequent Treatment Effect by Applying Inverse Probability of Censoring Weighting in the LATITUDE Study.

2022-01-063 citations

Impact of abiraterone acetate plus prednisone in patients with castration-sensitive prostate cancer and visceral metastases over four years of follow-up: A post-hoc exploratory analysis of the LATITUDE study

European Journal of Cancer2021-12-2229 citations

New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension

Lara D. Veeken2021-10-2750 citations

Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk.

2021-08-2119 citations

Treatment failure in giant cell arteritis.

2021-05-2830 citations

Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial.

2021-03-1971 citations

Adjusting Overall Survival Estimates for Treatment Switching in Metastatic, Castration-Sensitive Prostate Cancer: Results from the LATITUDE Study

Targeted Oncology2019-11-218 citations

Phase II Study of Single/Repeated Doses of Acumapimod (BCT197) to Treat Acute Exacerbations of COPD

COPD Journal of Chronic Obstructive Pulmonary Disease2019-11-0232 citations

ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer

Journal of Clinical Oncology2019-07-221114 citations

Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.

2019-04-12573 citations

Final analysis of phase III LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT).

Journal of Clinical Oncology2019-03-019 citations

2019-02-2029 citations

Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration‐naive prostate cancer: Results from LATITUDE

Cancer2018-12-061 citations

LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT+abiraterone acetate and prednisone (AAP) or placebo (PBO)

Annals of Oncology2018-10-015 citations

Longer term preplanned efficacy and safety analysis of abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC) from the phase 3 LATITUDE trial.

Journal of Clinical Oncology2018-05-204 citations

12 more papers not shown

Prednisone placebo

Sponsors

Conditions

Phase 2

Phase 3

Related Papers